Pharvaris NV (PHVS) Stock Analysis
Verdict: HOLD
Phase 3 clinical transition for oral HAE therapy offers a high-reward catalyst, but heavy insider selling near $31 raises a yellow flag.
Investment score: 64/100
Analysis as of
Is Pharvaris NV stock worth reviewing? The TradeMates thesis
Pharvaris is a pre-revenue biotech with a strong balance sheet and a high-potential oral HAE candidate. While analyst sentiment is overwhelmingly positive, recent heavy insider selling and technical resistance at 52-week highs suggest waiting for a better entry or further clinical de-risking.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 70/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Pharvaris NV opportunities and risks
What speaks for PHVS
- Phase 3 Prophylaxis Pivot
What speaks against PHVS
- Aggressive Insider Selling
Frequently asked questions about Pharvaris NV (PHVS)
Is PHVS stock a good investment?
The TradeMates model rates Pharvaris NV as HOLD with an investment score of 64/100. Pharvaris is a pre-revenue biotech with a strong balance sheet and a high-potential oral HAE candidate. While analyst sentiment is overwhelmingly positive, recent heavy insider selling and technical resistance at 52-week highs suggest waiting for a better entry or further clinical de-risking. This is algorithmic model output, not personal investment advice.
Is PHVS stock a buy?
The TradeMates model verdict for PHVS is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.